ArticleTranslational cancer research2025
Development and validation of prognostic models based on cell cycle-related signatures for predicting the prognosis of patients with lung adenocarcinoma.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung adenocarcinoma (LUAD) represents the most prevalent histological subtype within lung cancer. Nevertheless, the risk of postoperative metastasis and recurrence remains a substantial concern. We aimed to build the cell cycle-related competing endogenous RNA (ceRNA) networks and potential prognosis prediction models of LUAD, which might provide a valuable reference for studying the prognosis of LUAD. Methods: The RNA sequencing data of LUAD were procured from The Cancer Genome Atlas (TCGA) database and the differentially expressed RNAs were identified from the Ensembl genome browser 96 database [P<0.05 and |log2 fold change (FC)| >1]. The gene expression profile data were acquired from the Gene Expression Omnibus (GEO) repository. A gene set variation analysis was carried out to determine the differentially expressed genes (DEGs) (P<0.05) and a cell cycle-related ceRNA network of LUAD was constructed based on the DEGs. Least absolute shrinkage and selection operator (LASSO) analysis was conducted to acquire the optimized gene combination, a risk score (RS) prognostic risk prediction model was generated subsequently, and a Kaplan-Meier curve was developed to evaluate the efficacy of the RS model. Moreover, we constructed the 3- and 5-year prognostic models of nomogram using R3.6.1 "rms" package, the C-index was counted for accessing predictive capacity. Receiver operating characteristic (ROC) curves were used to evaluate the multiple prognostic risk prediction model. Results: In total, we identified 240 DEGs and constructed the cell cycle-related ceRNA network of LUAD from datasets GSE50081 and GSE37745. Six optimal genes ( Conclusions: This research identified six prognostic biomarkers and built the prognostic prediction models of LUAD, which may enhance the comprehension of disease biology, serve as an effective prognostic tool for LUAD and drive novel therapy development potentially.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.